(1-formyl-pentyl)-carbamic acid tert-butyl ester | 104062-70-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1-formyl-pentyl)-carbamic acid tert-butyl ester
• 英文别名: 2(S)-(tert-butoxycarbonylamino)hexanal；2(R)-tert-butoxycarbonylaminohexanal；tert-butyl N-(1-oxohexan-2-yl)carbamate
• CAS: 104062-70-6
• 化学式: C₁₁H₂₁NO₃
• mdl: MFCD09751782
• 分子量: 215.293
• InChiKey: OBMGXPJNZKYOQY-UHFFFAOYSA-N

物化性质

• 沸点：
  301.1±25.0 °C(Predicted)
• 密度：
  0.977±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-formyl-pentyl)-carbamic acid tert-butyl ester 在 N-甲基吗啉 、 盐酸 、 lithium hydroxide 、 sodium hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 {1-[({[((S)-Dimethylcarbamoyl-phenyl-methyl)-carbamoyl]-methyl}-carbamoyl)-hydroxy-methyl]-pentyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid

  摘要：

  Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of similar to 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.046
• 作为产物：
  描述：

  2-((tert-butoxycarbonyl)amino)hexanoic acid 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 13.0h， 生成 (1-formyl-pentyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid

  摘要：

  Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of similar to 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.046

文献信息

• [EN] PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES PEPTIDIQUES EN TANT QU'INHIBITEURS DE LA PROTEASE A CYSTEINE
  申请人：AXYS PHARM INC

  公开号：WO2004000838A1

  公开（公告）日：2003-12-31

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是卡特普辛B、K、L、F和S，因此在治疗由这些蛋白酶介导的疾病方面具有用途。本发明涉及包含这些化合物的药物组合物以及制备它们的方法。
• [EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
  申请人：AXYS PHARMACEUTICALS

  公开号：WO2004108661A1

  公开（公告）日：2004-12-16

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是包括B、K、L、F和S半胱氨酸蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面具有用处。本发明涉及包含这些化合物的药物组合物以及其制备方法。
• Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 2: Improvement of in vitro activity
  作者：Toshiki Murata、Mitsuyuki Shimada、Hiroshi Kadono、Sachiko Sakakibara、Takashi Yoshino、Tsutomu Masuda、Makoto Shimazaki、Takuya Shintani、Kinji Fuchikami、Kevin B Bacon、Karl B Ziegelbauer、Timothy B Lowinger

  DOI：10.1016/j.bmcl.2004.05.040

  日期：2004.8

  A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as IkappaB kinase beta (IKK-beta) inhibitors. Substitution of an aminoalkyl group for the aromatic group at the 4-position on the core pyridine ring resulted in a marked increase in both kinase enzyme and cellular potencies, and provided potent IKK-beta inhibitors with IC(50) values of below 100

  合成了一系列的2-氨基-3-氰基-4-烷基-6-（2-羟基苯基）吡啶衍生物，并将其评估为IkappaB激酶β（IKK-β）抑制剂。氨基吡啶基团取代核心吡啶环上4位的芳香族基团导致激酶酶和细胞效能的显着增加，并提供了具有低于100 nM的IC（50）值的强效IKK-β抑制剂。
• [EN] INHIBITORS OF PRENYL-PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE PRENYL-PROTEINE-TRANSFERASES
  申请人：MERCK & CO., INC.

  公开号：WO1999009985A1

  公开（公告）日：1999-03-04

  (EN) The present invention is directed to compounds which inhibit prenyl-protein transferases, farnesyl-protein transferase and geranylgeranyl-protein transferase type I, and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I and the prenylation of the oncogene protein RAS.(FR) L'invention concerne des composés qui inhibent les prényl-protéine-transférases, la farnésyl-protéine-transférase et la géranylgéranyl-protéine-transférase de type I, de même que la prénylation de la protéine oncogène Ras. L'invention concerne également des compositions chimiothérapeutiques renfermant les composés considérés, ainsi que des procédés permettant d'inhiber la farnésyl-protéine-transférase, la géranylgéranyl-protéine-transférase de type I et la prénylation de la protéine oncogène Ras.

  该发明涉及抑制异戊二烯基-蛋白质转移酶、法尼基-蛋白质转移酶和生长酰基-蛋白质转移酶I型以及癌基因蛋白Ras的异戊二烯基化的化合物。该发明还涉及含有该发明化合物的化疗组合物以及抑制法尼基-蛋白质转移酶、生长酰基-蛋白质转移酶I型和癌基因蛋白Ras的异戊二烯基化的方法。
• [EN] INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE FARNESYL-PROTEINE TRANSFERASE
  申请人：MERCK & CO., INC.

  公开号：WO1996030343A1

  公开（公告）日：1996-10-03

  (EN) The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.(FR) La présente invention concerne des composés qui inhibent la farnésyl-protéine transférase (FTase) et la farnélysation de l'oncogène Ras protéique. L'invention concerne en outre des compositions chimiothérapeutiques contenant les composés de cette invention, et des procédés servant à inhiber la farnésyl-protéine transférase et la farnélysation de la protéine d'oncogène Ras.

  该发明涉及抑制法尼酰-蛋白转移酶（FTase）和癌基因蛋白Ras的法尼酰化的化合物。该发明进一步涉及含有该发明化合物的化疗组合物和抑制法尼酰-蛋白转移酶和癌基因蛋白Ras的法尼酰化的方法。